PortViewPortView
Bruker logo

Bruker (BRKR) Stock Analysis

NASDAQHealthcareMedical - Devices

$58.45+4.32%
1-year price historyRange $29.35 – $64.34
52-week range$58.45
$28.53$65.30

What Bruker does

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.

Key metrics

Market cap
$8.90B
P/E (TTM)
29.37
EPS (TTM)
$1.99
Beta
1.27
Dividend yield
0.34%
Revenue / share
$22.99
50-day avg
$58.69
200-day avg
$47.77
52-week high
$65.30
52-week low
$28.53
CEO
Frank H. Laukien

ETFs linked to BRKR

Broad-market and Healthcare sector ETFs an investor holding Bruker is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BRKR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze BRKR in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Bruker?
Bruker trades under the ticker BRKR on NASDAQ.
Which exchange is BRKR listed on?
BRKR is listed on NASDAQ.
What sector does Bruker operate in?
Bruker is classified in the Healthcare sector (Medical - Devices industry).
How can PortView help analyze BRKR in a portfolio?
PortView shows BRKR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.